Table 3. Variables associated with overall survival in patients with HCC.
Variables | Category | Overall survival | |||
---|---|---|---|---|---|
Univariate analysis | Multivariate analysis | ||||
OR (95%CI) | P | OR (95%CI) | P | ||
Age (years) | < 50 vs. ≥ 50 | 0.70 (0.33–1.48) | 0.347 | ||
Gender | Male vs. Female | 1.17 (0.51–2.68) | 0.709 | ||
Aspartate aminotransferase (IU/L) | < 60 vs. ≥ 60 | 1.44 (0.68–3.05) | 0.342 | ||
Alanine aminotransferase (IU/L) | < 50 vs. ≥ 50 | 0.76 (0.36–1.60) | 0.465 | ||
Platelet count (109/L) | ≥ 140 vs. <140 | 1.81 (0.83–3.95) | 0.134 | ||
HBeAg positivity | Negative vs. Positive | 1.43 (0.65–3.18) | 0.376 | ||
Log10 HBV DNA (IU/mL) | < 4.0 vs. ≥ 4.0 | 0.69 (0.29–1.63) | 0.393 | ||
Child-Pugh classification | A vs. B and C | 1.26 (0.58–2.76) | 0.560 | ||
Alpha fetoprotein (ng/mL) | < 100 vs. ≥ 100 | 2.76 (1.26–6.07) | 0.011* | 1.28 (0.55–2.97) | 0.571 |
Tumor size (cm.) | <5.0 vs. ≥ 5.0 | 4.21 (1.52–11.68) | 0.006* | 0.99 (0.23–4.22) | 0.985 |
BCLC stage | 0-B vs. C, D | 5.74 (1.86–17.75) | 0.002* | 9.27 (1.99–43.14) | 0.005* |
miR-223-3p | ≥ 0.13 vs. < 0.13 | 4.38 (1.66–11.56) | 0.003* | 6.61 (2.36–18.55) | <0.001* |
miR-199a-5p | ≥ 0.46 vs. < 0.46 | 0.81 (0.38–1.72) | 0.589 | ||
miR-451a | ≥ 0.05 vs. < 0.05 | 1.03 (0.49–2.18) | 0.933 |